Division of Oncology
in the Department of Medicine
Welcome to the Division of Oncology, a center of excellence in patient care, medical education, and state-of-the-art research. Cancer is a major public health problem and it is also an exciting challenge for discovery and innovation.
Message from the Chief
A welcome message from the the Division of Oncology's Interim Chief, Dr. Heather Wakelee.
The Division of Oncology is seeking qualified faculty for several open positions. Successful applicants must hold an MD or MD/PhD degree and be board-certified or board-eligible in Medical Oncology, and have a history of significant peer-reviewed funding.
- To engage in research to create the future of cancer care
- To provide the best in care for cancer patients
- To train physicians for careers in academic medicine and research
IN THE NEWS
- Watch NBC for an update on Dr. Ronald Levy's upcoming cancer vaccine study
- Listen to Science Friday for an interview about the Levy lab's cancer vaccine discovery published in Science Translational Medicine on 1/31/18
- During a recent TedxPaloAlto talk, Idit Sagiv-Barfi, MD, PHD, an instructor of oncology, discussed the future of cancer vaccines.
- OncLive® recognizes Dr. Saul Rosenberg as a 2019 Giant of Cancer Care for his work in lymphoma. Winners will be celebrated at the seventh annual reception in Chicago on May 30. Read more here.
It is our pleasure to introduce a new faculty member in the Division of Oncology.
The Division of Oncology welcomes Dr. Saad Khan, an Assistant Professor of Medicine in the MCL line in the Head and Neck Oncology group, as of May 1, 2020. Dr. Kahn did his medical school training in Pakistan at Punjab Medical College, then completed Internal Medicine residency training at University of Massachusetts Medical Center. He did his oncology fellowship training at Temple University Health System/Fox Chase Cancer Center before joining the faculty at University of Texas Southwestern, Dallas where he has been since 2012. He is already well known to many of the faculty from his active participation in the Eastern Cooperative Oncology Group (ECOG-ACRIN). He is an active clinical trialist, with a focus on translational research opportunities in Head and Neck malignancies and has a strong research focus in thyroid cancers. We are delighted he will be joining the faculty.